Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia

American Journal of Cardiology

Volumn 79, Issue 9, 1997, Pages 1298-1301

  Mostaza, Jose M ^a   Schulz, Isio ^a   Vega, Gloria Lena ^a   Grundy, Scott M ^a  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PRAVASTATIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG FORMULATION; DRUG MECHANISM; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; HUMANS; HYPERLIPIDEMIAS; MIDDLE AGED; NIACIN; PRAVASTATIN; RISK FACTORS; TRIGLYCERIDES;

EID: 0030919418     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00109-4     Document Type: Article

References (19)

1. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease II: genetic analysis of the lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 52:1973;1544-1568.
2. Brunzell J, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res. 24:1983;147-155.
3. Cullen P, Farren B, Scott J, Farrall M. Complex segregation analysis provides evidence for a major gene acting on serum triglyceride levels in 55 British families with familial combined hyperlipidemia. Arterioscl Thromb. 14:1994;1233-1249.
4. Jarvick GP, Brunzell JD, Austin MA, Krauss RM, Motulsky AG, Wijsman E. Genetic predictors of FCHL in four large pedigrees. Influence of apo B level major locus predicted genotype and LDL subclass phenotype. Arterioscl Thromb. 14:1994;1687-1694.
5. Castro Cabezas M, de Bruin TW, de Valk HW, Shoulders CC, Jansen H, Willem Erkelens D. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest. 92:1993;160-168.
6. Reynisdottir S, Eriksson M, Angelin B, Arner P. Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia. J Clin Invest. 95:1995;2161-2169.
7. Bruchert E, de Gennes JL, Malbecq W, Baigts F. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. Clin Cardiol. 18:1995;621-629.
8. Vega GL, Grundy SM. Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations: comparison of gemfibrozil vs. lovastatin therapy. JAMA. 264:1990;2759-2763.
9. Vega GL, Grundy SM. Management of primary mixed hyperlipidemia with lovastatin. Arch Int Med. 150:1990;1313-1319.
10. Davignon J, Roederer G, Montigny M, Hayden MR, Tan MH, Connelly PW, Hegele R, McPhearson R, Lupien PJ, Gagne C, Little AJ, Collin P. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol. 73:1994;339-345.
11. Franceschini G, Cassinotti M, Vecchio G, Gianfranceschi G, Pazzucconi F, Mukarami T, Sirtori M, D'Acquarica AL, Sirtori CR. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscl Thromb. 14:1994;1569-1675.
12. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
13. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, McFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
14. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wu CC, Davis B, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
15. Manninen V, Tekanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation. 85:1992;37-45.
16. Martin-Jadraque R, Tato F, Mostaza J, Vega GL, Grundy SM. Effectiveness of low-dose crystalline nicotinic acid in men with low high-density lipoprotein cholesterol levels. Arch Int Med. 156:1996;1081-1088.
17. National Cholesterol Education Program: second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation. 89:1994;1329-1445.
18. Carlson LA, Bottinger LE. Risk factors for ischemic heart disease in men and women. Results of the 19-year follow-up of the Stockholm Prospective Study. Acta Med Scand. 218:1985;207-211.
19. East C, Bilheimer DW, Grundy SM. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med. 112:1990;228-230.